DoW Lupus, Idea Award
- Response deadline
- Aug 24, 2026 Closed
- Date posted
- May 5, 2026
- Source
- Open notice
Description
Summary: This funding mechanism supports innovative, high-risk/high-reward research that could ultimately lead to a critical discovery or major advancement relevant to lupus. The emphasis is on innovation. Research must address at least one of the fiscal year 2026 (FY26) Lupus Research Program (LRP) Idea Award (IA) focus areas. This funding mechanism does not allow clinical trials. Distinctive Features: • Early-career investigators are eligible to serve as Principal Investigators (PIs) on applications to the FY26 LRP Idea Award (see Section 2. Eligibility Information). • Preliminary data are permitted but not required. • Applications should describe future directions of the work. • An individual may be named as PI on only one application per LRP award mechanism (IA, Impact Award, Transformative Vision Development Award, Transformative Vision Award), for a maximum of four applications to the FY26 LRP
Classifications
- NAICS12.420
Documents (1)
- DownloadHT942526LRPIA_GG.pdfapplication/pdf645 KB
Contacts
- help@ebrap.org301-619-1139
Similar contracts
- DoW Breast Cancer, Breakthrough Award Levels 1 and 2Due Nov 18, 2026
- DoW Breast Cancer, Clinical Research Extension AwardDue Nov 18, 2026
- DoW Reconstructive Transplant, Investigator-Initiated Research AwardDue Nov 4, 2026
- DoW Neurofibromatosis Research Academy – Scholar AwardDue Sep 22, 2026
- DoW Neurofibromatosis Investigator-Initiated Research AwardDue Sep 22, 2026
- DoW Neurofibromatosis Exploration-Hypothesis Development AwardDue Sep 22, 2026